Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in MCI

• Status: Recruiting
• Trial end date: 2022-06-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Atorvastatin

Criteria

Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors:

• MCI defined by CDR of 0.5 or 1.0.

• Memory, processing speed, executive function, language - cognitive scores > 1.5 standard deviations below age-education norms.

• Not demented by history.

• Not taking statins currently or in the last 6 months.

• Cognitive/functional impairment not likely due to another neurological disease or delirium.

Exclusion Criteria:

• Taking a statin currently or have taken a statin in the last 6 months.

• Contraindications to taking a statin.

• Transplant patient taking cyclosporine.

• Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).

• Diagnosis of dementia by history.

• Current diagnosis of substance abuse.

• History of stroke or myocardial infarction in past 6 months.

• History of HIV.